Frontiers in Cardiovascular Medicine

FEBRUARY 19, 2025

Although heart transplantation can replace the damaged heart, its clinical application and promotion are limited by the source of donor, expensive cost, immune rejection, and ethical problems. It has become an urgent task for clinical medicine to seek new and better treatment.

Myocardial Infarction 52

Myocardial Infarction Quality of Life Heart Transplant Ischemia 52

Circulation: Cardiovascular Imaging

APRIL 2, 2024

BACKGROUND:In heart transplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after heart transplantation is associated with long-term adverse outcomes is unknown. years after heart transplantation were included.

Heart Transplant 40

Heart Transplant Transplant Outcomes Myocardial Infarction 40

DAIC

APRIL 30, 2024

Myocardial infarctions , commonly known as “heart attacks,” are on the rise, resulting in a significant number of deaths each year. Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart Attack 105

Circulation

JANUARY 18, 2024

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood.

Myocardial Infarction 45

Myocardial Infarction Heart Transplant Ischemia Transplant 45

All About Cardiovascular System and Disorders

FEBRUARY 24, 2024

Heart failure, heart transplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype. Higher incidence of hot phases were noted in left ventricular and biventricular phenotypes.

Cardiomyopathy 52

Cardiomyopathy Chest Pain Arrhythmia Heart Transplant 52

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). Here is our curated list of the top sessions.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

DAIC

APRIL 8, 2024

Previous trials evaluating the potential benefits of this and other heart pumps for cardiogenic shock have had mixed results. of those who received the Impella pump had died at six months after randomization; there was a 13 percentage point absolute reduction in the rate of death, the study’s primary endpoint, in favor of the heart pump.

Heart Attack 52

Heart Attack Heart attacks Cardiogenic Shock Catheterization Laboratory 52